Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07035093 · ClinicalTrials.gov registry record · Phase 3
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 586
- Enrollment target
- 20
- Study locations
NCT07035093: Recruiting Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT07035093 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 586 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07035093, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 586 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retatrutide
Study Locations (20)
Florida
- K2 Medical Research - Daytona Beach - Daytona Beach
- Flourish Research - Miami, LLC - Miami
- IMA Clinical Research St. Petersburg - St. Petersburg
- Care Access - Tampa - Tampa
- Charter Research - Lady Lake - The Villages
- Conquest Research - Winter Park
California
- Ark Clinical Research - Fountain Valley - Fountain Valley
- St Joseph Heritage Healthcare - Fullerton
- Clinical Research Institute - Los Angeles
- Artemis Institute for Clinical Research - San Diego
Arizona
- MD First Research - Chandler - Chandler
- Tucson Orthopaedic Institute - North Wyatt Drive - Tucson
Colorado
- Alpine Clinical Research Center - Boulder
Kansas
- Cotton O'Neil Clinical Research Center - Topeka
Louisiana
- Care Access - Lake Charles (Bayou Pines) - Lake Charles
Massachusetts
- MedVadis Research Corporation - Waltham
Michigan
- Great Lakes Research Group, Inc. - Bay City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 586 participants |
| Start Date | 2025-05-29 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
What NCT07035093 shows while recruiting
NCT07035093 is an interventional study that assigns participants to a tested intervention. The registered 586 participants enrollment target is mid-sized for trials with a published cap, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (28% lower).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07035093 names 20 study sites across 11 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT07035093 about?
NCT07035093 is a clinical study titled "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain". The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
What is the current status of trial NCT07035093?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 586 participants. The study started on 2025-05-29. Estimated completion is 2027-09.
What conditions does trial NCT07035093 study?
This clinical trial studies the following conditions: Obesity, Overweight, Chronic Low Back Pain (CLBP).
What interventions are being tested in trial NCT07035093?
The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT07035093?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07035093 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07035093's enrollment target sits among peer trials
586 122nd of 1053 higher than 932 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
- NCT06183281 · 586 participants · NA
Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity
- NCT06976203 · 586 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI